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Glutamoptosis is the induction of apoptotic cell death as a consequence of the aberrant
activation of glutaminolysis and mTORC1 signaling during nutritional imbalance in pro-
liferating cells. The role of the bioenergetic sensor AMPK during glutamoptosis is not defined
yet. Here, we show that AMPK reactivation blocks both the glutamine-dependent activation
of mTORC1 and glutamoptosis in vitro and in vivo. We also show that glutamine is used for
asparagine synthesis and the GABA shunt to produce ATP and to inhibit AMPK, indepen-
dently of glutaminolysis. Overall, our results indicate that glutamine metabolism is connected
with mTORC1 activation through two parallel pathways: an acute alpha-ketoglutarate-
dependent pathway; and a secondary ATP/AMPK-dependent pathway. This dual metabolic
connection between glutamine and mTORC1 must be considered for the future design of
therapeutic strategies to prevent cell growth in diseases such as cancer.
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Among all amino acids, glutamine is the most abundant inthe blood1–3. The importance of glutamine for cancer cellsgrowth has been extensively described and linked to its
role as a precursor for α-ketoglutarate (αKG) to sustain the tri-
carboxylic acid (TCA) cycle. Indeed, glutamine is mainly meta-
bolized through glutaminolysis in a two-step reaction: first the
enzyme glutaminase (GLS) catalyzes the hydrolysis of glutamine
to glutamate; and then glutamate is converted to αKG through an
oxidative deamination reaction catalyzed by the enzyme gluta-
mate dehydrogenase (GDH). Another amino acid, leucine, acts as
an allosteric activator of the second enzyme, being consequently
necessary for glutaminolysis induction4,5.
Although glutamine can participate in the synthesis of different
amino acids through the production of glutamate, only aspar-
agine requires glutamine for de novo synthesis. Asparagine syn-
thetase (ASNS) is the enzyme that converts glutamine and
aspartate into glutamate and asparagine in an ATP-dependent
manner6. ASNS expression is upregulated during amino acid
starvation through the activation of activating transcription factor
4 (ATF4)7. Asparagine has been identified as an exchange amino
acid factor that regulates the serine/threonine kinase mammalian
target of rapamycin complex 1 (mTORC1), nucleotide bio-
synthesis and proliferation7.
The role of GABA shunt is a bypass for two steps of the TCA
cycle, wherein GABA is synthesized from glutamate by a GAD1-
encoded decarboxylase, transaminated into succinic semi-
aldehyde, and metabolized into the TCA cycle intermediate
succinate8. In addition to its role as a neurotransmitter, GABA
has been detected in a wide range of peripheral tissues9 and
recently linked to castration-resistant prostate cancer progression
through the regulation of nuclear androgen receptor by GABA10.
That study reported that GABA shunt is upregulated in response
to the activating phosphorylation of GAD65 by the PI3K path-
way. In a different cancer type, the increased uptake and meta-
bolism of GABA in breast to brain metastatic cells was linked to
an increase of NADH levels in the microenvironment conferring
a proliferative advantage to the tumor11.
Previously, our results demonstrated that glutamine, and most
particularly its catabolic conversion to αKG through glutamino-
lysis, activates mTORC1 at the short and long-term5,12. mTORC1
is a major signaling hub that integrates different inputs, such as
nutrients, oxygen, energy, and growth factors, to regulate the
metabolic pathways controlling cell growth and proliferation13.
As mTORC1 is over-activated in 80% of solid tumors14, different
analogs of its inhibitor rapamycin have been developed to inhibit
mTORC1 in patients. At a clinical level, the results remain
modest and a clear need for co-therapies has been described15–17.
Our previous work determined that the activation of mTORC1 by
glutaminolysis during nutritional imbalance lead to the anom-
alous inhibition of autophagy and a subsequent form of apoptosis
named glutamoptosis12,18. But still, the impact of glutamine
metabolism on the bioenergetic status of the cells during long-
term mTORC1 activation and glutamoptosis induction remains
to be defined.
Eukaryotes have developed a system to sense low ATP levels
via another serine/threonine kinase, the AMP-activated protein
kinase (AMPK) complex. Under low intracellular ATP levels,
AMP or ADP can directly bind to the γ regulatory subunit of
AMPK, leading to a conformational change that allows the acti-
vating phosphorylation of AMPK13. Once activated, AMPK
redirects the metabolism towards the increase of catabolism and
the decrease in anabolism through phosphorylation of down-
stream key protein pathways, ultimately leading to mTORC1
inhibition13.
Herein, we report that the amino acid glutamine is sufficient to
sustain the production of ATP in absence of any other amino
acid, following a glutaminolysis-independent mechanism. During
glutamine sufficiency, ASNS and GABA shunt are responsible for
metabolizing glutamine to generate ATP and to inhibit AMPK.
Thus, our results indicate that glutamine activates mTORC1
following a two branches mechanism: a short-term mechanism
involving αKG production, and a long-term mechanism involving
ASNS, GABA, and AMPK.
Results
Glutaminolysis sustains the production of ATP to inhibit
AMPK and to activate mTORC1. Previously, we showed that the
addition of leucine and glutamine (“LQ treatment”) to amino
acid-starved cells is sufficient to activate glutaminolysis and
subsequently mTORC15,19. To better understand the role of the
bioenergetic status of the cell in this pathway, we first investigated
if LQ treatment impacted the production of ATP in the cell and
the activation of AMPK. Confirming our previous observations,
short-term (2 h) amino acid starvation had no effect in the levels
of ATP in cultured cells. However, we observed that, at longer
times, amino acid withdrawal significantly decreased ATP/ADP
ratio in U2OS and HCT116 cellular models (Fig. 1A, B and
Supplementary 1A, B). LQ addition in amino acid-starved cells
sustained the levels of ATP at 4, 8, 12, 24, 48, and 72 h (Fig. 1C
and Supplementary 1C–E). By contrast, the addition of methio-
nine or arginine, two amino acids which have been reported to
activate mTORC1 at short-term, did not sustain the production
of ATP (Supplementary 1F, G). Measurements of glutamine and
leucine levels in the medium indicated that these amino acids
remained fully available even after 72 h of LQ treatment (Sup-
plementary 1H–I). In agreement to these previous observations,
we also observed that LQ treatment increased the basal respira-
tion of U2OS cells compared to amino acid starvation (Fig. 1D).
The maximal oxygen consumption rate (OCR) was also increased
in the presence of LQ, which resulted in an increase of ATP
production linked to respiration (Fig. 1E). Thus, we concluded
that long-term glutaminolysis, even in the absence of any other
amino acid, was sufficient to increase the respiratory capacity and
the production of ATP in the cell.
We next investigated if the observed production of ATP in LQ-
treated cells had any impact on the phosphorylation of AMPK.
The removal of amino acids from the culture medium led to the
inhibition of mTORC1 in U2OS cells, as broadly reported
before20, but concomitantly it led also to the phosphorylation of
AMPK at threonine 172 (Fig. 1F), in agreement with the observed
decrease in ATP levels. Accordingly, the phosphorylation of
AMPK was reverted by the addition of LQ, which again
correlated with the increase in ATP levels in this condition
(Fig. 1F). The LQ-induced inhibition of AMPK was observed at
24, 48, and 72 h (Fig. 1G). Long-term activation of mTORC1
downstream of AMPK during LQ treatment was confirmed by
the phosphorylation of its target proteins S6K, S6, and 4EBP1
(Fig. 1F, G), and by its translocation at the surface of the lysosome
using LAMP2 (Fig. 1H, I) or CD63 (Supplementary 1J, K) as
lysosomal markers. To confirm a mechanistic role of AMPK
during LQ-mediated mTORC1 activation at long-term, we
investigated the status of mTORC1 by the addition of the AMPK
activator AICAR in LQ-treated U2OS and HCT116 cells. As
observed in Fig. 1J and Supplementary 1L, reactivation of AMPK
using AICAR was sufficient to prevent the LQ-mediated
activation of mTORC1. Similar results were obtained by
transfecting a MYC-tagged constitutively active form of AMPK
(CA-AMPK, kindly provided by Prof. Benoit Viollet, Paris,
France) (Fig. 1K) or using other AMPK activators, such as
metformin or A769662 (Fig. 1L). Surprisingly, the ablation of
AMPK using AMPK−/− MEFs (again, kindly provided by Prof.
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Benoit Viollet) also prevented the LQ-mediated activation of
mTORC1 (Supplementary 1M). This result suggested that, in
addition to acting as a negative regulator of mTORC1, the
presence of AMPK is necessary for the connection between
glutamine metabolism and mTORC1, underscoring the complex-
ity of the metabolic adaptations in these circumstances.
We also confirmed that this AMPK-regulated activation of
mTORC1 during long-term LQ treatment had a direct physio-
logical impact in the cell in terms of autophagy activation, a key
process during glutamoptosis induction12. As observed in Fig. 1M,
N, LQ-treated U2OS cells stably expressing the autophagic
reporter GFP-LC3 displayed an increase of GFP-LC3 aggregates
upon AMPK reactivation using AICAR, metformin, or A769662.
Consistently, reactivation of AMPK using these different
activators also decreased the levels of endogenous p62 and
LC3I, increasing LC3II formation (Fig. 1L), well-known autop-
hagy markers. We also evaluated the autophagic flux using
bafilomycin A1 (Baf A1) to trap the formation of autophago-
somes. The inhibition of autophagy using Baf A1 led to a greater
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reactivation of AMPK using AICAR concomitantly to Baf A1 and
LQ did not accumulate p62 at the same level (Fig. 1O), and
restored the levels of LC3II. Altogether, these results showed that
long-term LQ treatment was sufficient to increase the levels of
ATP, leading to the inhibition of AMPK. AMPK inhibition in
LQ-treated cells led to the subsequent activation of mTORC1 and
the inhibition of autophagy, two major processes controlling
glutamoptosis.
AMPK inhibition is necessary for glutamoptosis both in vitro
and in vivo. Next, we assessed the role of AMPK in the induction
of apoptosis following the activation of mTORC1 by glutami-
nolysis during nutritional imbalance, i.e., glutamoptosis. In
agreement with our previous results12, long-term LQ treatment in
absence of any other amino acid decreased cell viability (Fig. 2A,
B). The LQ-induced increase in cell death was prevented by
AMPK reactivation using AICAR, metformin, or A769662
(Fig. 2A, B). Further, a clonogenic assay confirmed that the
pharmacological reactivation of AMPK prevented LQ-mediated
cell death induction (Fig. 2C, D). AMPK reactivation was also
sufficient to prevent apoptosis induced by LQ, as determined by
the decrease in the double annexin V/PI staining observed by flow
cytometry (Fig. 2E, F), and by the decrease in the pro-apoptotic
markers cleaved PARP and cleaved caspase 3 (Fig. 2G). On the
contrary, AMPK ablation did not increase the induction of cell
death during amino acid withdrawal, as mTORC1 inhibition and
subsequent autophagy activation under these conditions pre-
vented glutamoptosis (Supplementary 2A). This result further
positioned mTORC1/autophagy downstream of AMPK during
glutamoptosis induction. These results were confirmed using
ATG5−/− MEFs in which the impairment of autophagy com-
pletely abolished the capacity of AICAR to promote cell survival
during amino acids starvation (Fig. 2H, I) as autophagy is
necessary as survival mechanism. Thus, AMPK inhibition
upstream of mTORC1/autophagy was necessary for gluta-
moptosis in vitro.
The participation of AMPK in glutamoptosis was also
investigated in vivo using implanted tumors in xenograft mouse
models. Two different cohorts of mice were implanted in the right
dorsal flank with HCT116 cells. Mice were treated with either
vehicle or with a cell-permeable αKG derivative, dimethyl-αKG
(DMKG) to induce glutamoptosis in vivo. Mice were then co-
treated with the mTORC1 inhibitor temsirolimus (a rapamycin
derivative) or with metformin. First, the induction of mTORC1
by DMKG was assessed by the analysis of S6 phosphorylation in
these tumors. As expected, the injection of DMKG in mice
induced the activation of mTORC1. A decrease of S6 phosphor-
ylation and thus mTORC1 activation was observed in mice co-
treated with temsirolimus or metformin (Fig. 2J, K and
Supplementary 2B). Second, the in vivo induction of glutamop-
tosis was assessed by immunohistochemical analysis of cleaved
caspase 3. We confirmed that DMKG treatment induced an
increase in apoptotic cell death in xenograft tumors in vivo, as
assessed by caspase 3 cleavage (Fig. 2L–M and Supplemen-
tary 2C). This is a validation of the physiological relevance of
glutamoptosis in vivo, confirming that glutamoptosis can be used
as a potential tool to induce tumoral cell death in vivo.
Furthermore, as shown in Fig. 2L–M and Supplementary 2C,
we also confirmed that the inhibition of mTORC1 using
temsirolimus prevented glutamoptosis in vivo, similar to what
we observed in cultured cells12. This result validated the
physiological model by which the aberrant activation of mTORC1
during nutritional imbalance induces apoptotic cell death in
animal models. Finally, and of note, AMPK reactivation using
metformin which was confirmed by IHC on T172 AMPK
phosphorylation (Supplementary 2D, E) was similarly sufficient
to prevent glutamoptosis in vivo (Fig. 2L–M and Supplemen-
tary 2C). Altogether, these data confirmed the necessity of AMPK
inhibition for glutamoptosis induction both in vitro and in vivo.
Glutaminolysis is not necessary for LQ-mediated ATP pro-
duction. After confirming the capacity of LQ to sustain ATP
levels, we investigated the possible role of glutaminolysis, the
main pathway to catabolise glutamine, in the production of ATP
in response to LQ. For this purpose, and following a loss-of-
function approach, we inhibited GLS either pharmacologically or
genetically (using two different inhibitors, BPTES and DON, or
RNA-interference mediated knockdown). We then investigated
the capacity of LQ treatment to induce ATP levels in GLS-
inhibited cells. Surprisingly, the inhibition of GLS did not prevent
the production of ATP in response to LQ in U2OS, HCT116 or
HEK293 cells (Fig. 3A, B and Supplementary 3A, B). Confirming
Fig. 1 Glutaminolysis sustains the production of ATP to inhibit AMPK and to activate mTORC1. A ATP/ADP ratio of U2OS cells incubated in the
presence or the absence of all amino acids for 2 or 72 h. Fed cells (C) are used as control. B ATP/ADP ratio of U2OS cells incubated in absence of amino
acid for the indicated time. C ATP/ADP ratio of amino acid-starved U2OS cells incubated in the presence or absence of LQ during the indicated times.
D OCR analysis by Seahorse® technology of amino acid-starved U2OS cells incubated in the presence (blue) or absence (purple) of LQ during 72 h. OCR
was measured either in basal conditions or after the injection of oligomycin, FCCP, and rotenone/antimycin A. Data are mean ± SEM of three biologically
independent experiments performed with five replicates. E Basal respiration used to drive ATP production as determined by OCR quantification of data
obtained in (D). F Immunoblot of mTORC1 activity markers (S6K, S6, and 4EBP1 phosphorylation) and AMPK phosphorylation of U2OS cells incubated
with or without amino acids, in the presence or absence of LQ during 72 h. G Immunoblot of mTORC1 activity markers (S6K and S6 phosphorylation) and
AMPK phosphorylation of amino acid-starved U2OS cells incubated in the presence or absence of LQ during 24, 48, or 72 h. H Immunofluorescence
microscopy captions of U2OS cells incubated with or without amino acids, in the presence or absence of LQ during 72 h. Cells were stained against LAMP2
(lysosomal marker, red), mTORC1 (green) and DAPI (blue). Scale bar represents 10 µm. I Quantification of the colocalization between LAMP2 and
mTORC1 as shown in (H). Person’s R value was evaluated using ImageJ coloc2 plugin on 25 ROI in three biologically independent experiments (75 ROI in
total per condition). J Immunoblot of mTORC1 activity markers (S6K and S6 phosphorylation) and AMPK phosphorylation of amino acid-starved U2OS
cells incubated in the presence or absence of LQ, with or without AICAR, during 72 h. K Immunoblot analysis of mTORC1 activity marker (S6
phosphorylation) of U2OS cells expressing a myc-tagged, constitutively active AMPK mutant in the presence or absence of amino acids and LQ as
indicated. L Immunoblot of autophagy (p62 and LC3-I/II) and mTORC1 (S6K and S6 phosphorylation) markers of amino acid-starved U2OS cells incubated
in absence or presence of LQ, AICAR, metformin or A769662 for 72 h, as indicated. M Fluorescence microscopy captions of GFP-LC3 expressing amino
acid-starved U2OS cells incubated in the presence or absence of LQ, with or without AICAR, metformin or A769662 for 72 h. Autophagosome formation
upon GFP-LC3 aggregation was assayed using confocal microscopy. The scale bar represents 10 µm. N Quantification of the number of GFP-LC3 dots per
cell of captions obtained in (M). >100 cells were counted per experiment. O Immunoblot analysis of autophagy markers (p62 and LC3I/II) of U2OS cells
treated with LQ, AICAR and/or Bafilomycin A1 as indicated for 72 h. Graphs show mean values ± SEM (n= 3 biologically independent experiments). *p <
0.05 (ANOVA analysis followed by a post hoc Bonferroni test). Source data are provided as a Source Data file.
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this result, silencing GDH did not impair the production of ATP
in LQ-treated cells either (Fig. 3C). Thus, glutaminolysis did not
show a necessary role for the capacity of LQ to sustain ATP levels.
Further confirming this conclusion, we also observed that the
addition of DMKG to amino acid-starved cells did not sustain the
production of ATP to a similar extent than LQ treatment (Fig. 3D
and Supplementary 3C, D). Hence, glutaminolysis was neither
necessary nor sufficient to sustain ATP production. The lack of
decrease on ATP levels upon glutaminolysis inhibition correlated
with an absence of AMPK reactivation (Fig. 3E, F), confirming
that glutaminolysis did not mediate the connection between LQ
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Glutamine is sufficient to sustain ATP levels, but not to acti-
vate mTORC1. During LQ treatment, leucine addition plays an
allosteric activation role for GDH, necessary for αKG production5,21.
As we concluded that glutaminolysis did not affect the ATP/AMPK
pathway, we then assessed whether leucine had any role in ATP levels
during LQ treatment. For this purpose, we treated amino acid-starved
U2OS, HCT116 and HEK293A cells with glutamine or leucine, and
subsequently measured ATP levels. Unlike leucine, glutamine alone
was sufficient to sustain ATP levels in all three cell lines (Fig. 4A and
Supplementary 4A, B). Confirming this result, we observed that basal
respiration of the cells in amino acid starvation did not change in
response to leucine addition (Fig. 4B). However, cells in the presence
of glutamine showed a significant increase of the respiratory activity,
independently of the presence or the absence of leucine (Fig. 4B).
Similarly, glutamine sufficiency induced a clear increase of the OCR
linked to ATP production by the mitochondria to meet the energetic
needs of the cell (Fig. 4C). This increase of ATP levels by glutamine
alone also correlated with an increase of endoplasmic reticulum cal-
cium pool due to the activity of the sarcoendoplasmic reticulum Ca2+
ATPase (SERCA) (Supplementary 4C). In a similar manner, and
correlating with ATP levels, a strong decrease of AMPK phosphor-
ylation was observed upon glutamine addition to otherwise amino
acid-depleted cells, while the addition of leucine did not reduce the
phosphorylation status of AMPK (Fig. 4D and Supplementary 4D).
Fig. 2 AMPK inhibition is necessary for glutamoptosis both in vitro and in vivo. A Representative microscopy images of amino acid-starved U2OS cells
incubated in absence or presence of LQ, AICAR, metformin, or A769662 for 72 h, as indicated. Scale bar represents 100 µm. B Cell viability as estimated by
a trypan blue exclusion assay of amino acid-starved U2OS cells incubated in the presence or absence of LQ and AICAR during 72 h. C Representative
images of clonogenic assay of U2OS cells treated as in (B). D Colony quantification of images obtained in (C). E Quantification of late apoptosis population
of three biologically independent experiments (double positive, annexin V and PI) as obtained in (F) for the indicated condition. F Flow cytometry analysis
of annexin V/PI staining of amino acid-starved U2OS cells incubated with or without LQ in combination with AICAR, metformin, or A769662 during 72 h.
G Immunoblot of the pro-apoptotic markers (BAX, cleaved caspase 3, and cleaved PARP), mTORC1 activity markers (Raptor, S6K, and S6
phosphorylation), and AMPK phosphorylation of amino acid-starved U2OS cells incubated in the presence or absence of LQ, with or without AICAR, during
72 h. H Cell viability as estimated by a trypan blue exclusion assay of ATG5+/+ and ATG5−/− MEFs incubated in the presence or absence of amino acids
(AA) and AICAR during 72 h. I Immunoblot analysis of pro-apoptotic markers of ATG5+/+ and ATG5−/− MEFs incubated as in (H). J–L Representative
immunohistochemistry microscopy pictures (×40 magnification) of xenograft tumors of mice treated as indicated (TEM: Temsirolimus; MET: Metformin).
Samples were stained against S6-pS235/236 (J) and cleaved caspase 3 (L). Scale bars represent 100 µm. K–M IHC visual score of S6-pS235/236 (K) and
caspase 3 (M) of images from (J) and (L), respectively. The upper and lower limits of the boxes represent quartiles, with the line within the boxes
indicating the median and the whiskers showing the extremes (n≥ 10 images per treatment). Graphs show mean values ± SEM (n= 3 biologically








































































































































































Fig. 3 Glutamine is sufficient to sustain ATP levels, but not to activate mTORC1. A ATP/ADP ratio of amino acid-starved U2OS cells incubated in the
presence or absence of LQ with or without BPTES or DON during 72 h. B, C GLS or GDH expressions were knocked down using small interfering RNA
(siRNA) in U2OS cells for 48 h. Cells were then treated with LQ for 72 h and the ATP/ADP ratio was measured. Scramble non-targeting siRNA was used as
a control. Immunoblots of GLS or GDH levels are presented as a control of the knockdown. D ATP/ADP ratio of amino acid-starved U2OS cells treated with
LQ or DMKG for 72 h. E, F Immunoblot of amino acid-starved U2OS cells treated with or without LQ in combination with BPTES (E) or DON (F) for 72 h.
Activity markers of AMPK and mTORC1 were analysed. Graphs show mean values ± SEM (n= 3 biologically independent experiments). *p < 0.05 (ANOVA
analysis followed by a post hoc Bonferroni test). Source data are provided as a Source Data file.
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Similar to what was observed for LQ treatment (Fig. 3B, C), gluta-
minolysis inhibition by GLS1 or GDH knockdown did not affect the
capacity of glutamine sufficiency to induce ATP levels in U2OS and
HCT116, confirming that glutaminolysis was not necessary for
glutamine-dependent ATP production (Supplementary 4E–H). It is
worth noting that neither glutamine alone nor leucine alone (in
absence of any other amino acid) were sufficient to activate mTORC1
after 72 h in either U2OS or HCT116 cells (Fig. 4D and Supple-
mentary 4D). Consistently, mTORC1 localization at the surface of the
lysosome was only observed in the presence of both leucine and
glutamine, but it was not observed if only one of these amino acids







































































































































































































































Fig. 4 Glutamine metabolism activates mTORC1 following two parallel, necessary branches. A ATP/ADP ratio of amino acid-starved U2OS cells
incubated with leucine and/or glutamine during 72 h. B OCR analysis by Seahorse® technology of amino acid-starved (purple) U2OS cells incubated with
leucine (red) and/or glutamine (Q green, LQ blue) during 72 h. OCR was measured either in basal conditions or after the injection of oligomycin, FCCP, and
rotenone/antimycin A. Data are mean ± SEM of three biologically independent experiments performed with five replicates. C Basal respiration used to drive
ATP production as determined by OCR quantification of data obtained in (B). D Immunoblot of mTORC1 activity markers (S6K and S6 phosphorylation)
and AMPK phosphorylation of amino acid-starved U2OS cells incubated with leucine and/or glutamine during 72 h. E Immunofluorescence microscopy
captions of U2OS cells incubated with leucine and/or glutamine during 72 h. Cells were stained against LAMP2 (lysosomal marker, red), mTORC1 (green)
and DAPI (blue). Scale bar represents 10 µm. F Quantification of the colocalization between LAMP2 and mTORC1 as shown in (E). Person’s R value was
evaluated using ImageJ coloc2 plugin on 25 ROI in three biologically independent experiments (75 ROI in total per condition). G Fluorescence microscopy
captions of GFP-LC3 expressing amino acid-starved U2OS cells incubated in the presence of glutamine and/or leucine during 72 h. Autophagosome
formation upon GFP-LC3 aggregation was assayed using confocal microscopy. The scale bar represents 10 µm. H Quantification of the number of GFP-LC3
dots per cell of captions obtained in (G). >100 cells were counted per experiment. I Immunoblot of autophagy (p62 and LC3-I/II) markers of amino acid-
starved U2OS cells incubated in the presence of glutamine and/or leucine during 72 h. J U2OS cells were transfected with RagB WT plasmid or RagB 54 L
plasmid. Amino acid-starved cells were then incubated with or without glutamine for 72 h. Downstream targets of mTORC1 (S6K and S6 phosphorylation)
were assessed by immunoblot. Graphs show mean values ± SEM (n= 3 biologically independent experiments). *p < 0.05 (ANOVA analysis followed by a
post hoc Bonferroni test). Source data are provided as a Source Data file.
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than for LQ, glutamine levels were measured in the cell culture
medium during glutamine sufficiency condition to verify the avail-
ability of this amino acid even after 3 days of treatment
(Supplementary 4K). Autophagy analysis downstream of mTORC1
also confirmed the inability of glutamine sufficiency to activate
mTORC1. Thus, long-term glutamine addition did not inhibit
autophagy activation during amino acid starvation, as assessed by the
autophagy reporter GFP-LC3 by confocal microscopy, and by
immunoblot analysis of the autophagic endogenous markers p62 and
LC3I/II. In contrast, and as shown previously, the addition of both
leucine and glutamine strongly decreased the number of GFP-LC3
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It is well documented that the re-addition of leucine alone for
10–30 m after a short-term amino acid starvation (1–2 h) is
sufficient to activate mTORC122–25. However, our data showed
that this reactivation of mTORC1 disappeared after longer
starvation periods (>4 h of amino acid starvation) (Supplemen-
tary 4L), which correlated with a strong decrease of glutamine
intracellular levels following 4 h of amino acid starvation
(Supplementary 4M). In contrast, re-addition of both leucine
and glutamine activated mTORC1 even after longer periods of
amino acid starvation (Supplementary 4N). These results support
a model by which leucine alone activates mTORC1 after short-
term amino acid starvation thanks to the remaining pool of
intracellular glutamine. It has been proposed elsewhere that
intracellular glutamine is required for leucine uptake26. However,
our data showed that, in our setup, intracellular levels of leucine
were not significantly affected by the co-addition of glutamine in
starved cells (Supplementary 4O), suggesting that intracellular
glutamine was not necessary for leucine uptake. Rather, our data
sustained a model by which leucine only activates mTORC1 by
cooperating with glutamine to activate glutaminolysis.
Glutamine metabolism activates mTORC1 following two par-
allel, necessary branches. In light of our results, we investigated
the possibility that two parallel pathways connect glutamine and
mTORC1: a previously reported glutaminolysis-dependent
branch; and an ATP-dependent but GLS/GDH-independent
branch. We previously showed that glutaminolysis activates
mTORC1 via RagB. Thus, αKG generation by glutaminolysis
increases GTP loading of RagB, leading to mTORC1 transloca-
tion to the surface of the lysosome5. It is documented that the
overexpression of a constitutively GTP-bound mutant variant of
RagB (RagB-GTP mutant) is sufficient to force the translocation
of mTORC1 to the surface of the lysosome even in amino acid-
starved cells27. The expression of this RagB-GTP mutant is suf-
ficient to activate mTORC1 in amino acid-starved cells at short
times (1–2 h)5,27. However, we observed that RagB-GTP mutant
expression did not activate mTORC1 in amino acid-starved cells
at longer times (72 h, Fig. 4J and Supplementary 4P). Strikingly,
the combination of both RagB-GTP expression and glutamine
addition induced the full activation of mTORC1 at 72 h, as
determined by the phosphorylation of the downstream targets
S6K and S6 (Fig. 4J). Similar results were obtained using a RagD-
GDP mutant, which also upregulates the lysosomal translocation
of mTORC1 (Supplementary 4P). Opposite to what we observed
with glutamine, the combination of both RagB-GTP and leucine
did not induce the activation of mTORC1 signaling (Supple-
mentary 4Q). These results further sustained a model by which
glutaminolysis (activated by both glutamine and leucine) is
necessary to produce αKG and to induce the Rag-mediated
translocation of mTORC1 at the surface of the lysosome. On the
other hand, glutamine, independently of GLS and GDH, sustains
the production of ATP and the inhibition of AMPK, necessary for
the full activation of mTORC1 at the surface of the lysosome,
mediated by the mTORC1 coactivator Rheb28.
ASNS and GABA shunt are alternative pathways to metabolize
glutamine. So far, our results indicated that glutamine sufficiency
produces ATP through mitochondrial activity, but glutaminolysis
was not necessary for this. To uncover the pathways involved in
glutamine-induced ATP production, we performed a metabo-
lomics analysis (Fig. 5A). We observed that, during amino acid
starvation (72 h), the levels of a large number of metabolites
dropped. Addition of leucine did not restore the vast majority of
them, again confirming that leucine has mostly an allosteric role,
not having a significant impact on the metabolism of the cell by
itself. In contrast, the addition of glutamine changed completely
the pattern, allowing us to identify a group of metabolites which
levels raised very high, particularly GABA, asparagine, glutamate
and aspartate (Fig. 5A and Supplementary 5A–F). This result
indicated an increased synthesis of asparagine, mediated by the
activity of ASNS, responsible for the production of asparagine
and glutamate from glutamine and aspartate (Supplemen-
tary 5G). To experimentally test this possibility, we traced glu-
tamine during glutamine sufficiency in U2OS cells using [U13C]-
glutamine. As expected, we observed an accumulation of both
glutamate m+ 5 and asparagine m+ 4 in the intracellular extract
of U2OS cells after 72 h of treatment. Further, glutamine suffi-
ciency also produced m+ 4 labeled aspartate (Fig. 5B), indicating
that aspartate used by ASNS was indeed originated (recycled)
from the glutamate through oxaloacetate generation at the TCA
cycle. Glutamate produced by ASNS was further converted into
aspartate likely through the activity of the enzyme aspartate
transaminase (GOT1) (Supplementary 5G). In parallel, we also
incubated amino acid-starved cells in the presence of [15N2]-
glutamine for 72 h. In agreement with our previous observations,
we observed a large accumulation of 15N-asparagine, confirming
the implication of ASNS in the metabolization of glutamine
during glutamine sufficiency (Fig. 5C). The production of both
15N-aspartate and 15N-asparagine in this condition finally
Fig. 5 ASNS and GABA shunt are alternative pathways to metabolize glutamine. A Heatmap representation of metabolite levels, as determined by
LC–MS analysis, in amino acid-starved U2OS cells incubated with glutamine and/or leucine. The heatmap was created with MetaboAnalyst3.0 with the
total pools of the detected metabolites. B 13C-labeled metabolite levels, as determined by LC–MS analysis, in U2OS cells incubated with or without all
amino acids or leucine alone as indicated, in the presence of (U)-13C-glutamine during 72 h. Total ion counts of glutamate m+ 5, asparagine m+ 4,
aspartate m+ 4, GABA m+ 4, citrate m+ 4, and malate m+ 4 are graphed. The percentage of labeling with respect to total metabolite levels is shown in
parenthesis for each metabolite. C 15N-labeled metabolite levels, as determined by LC–MS analysis, in U2OS cells incubated with or without all amino acids
or leucine alone as indicated, in the presence of 15N2-glutamine during 72 h. Ion counts of 15N -glutamate, 15N -asparagine, 15N aspartate, and 15N2-
asparagine are plotted. The percentage of labeling relative to the total metabolite is shown in parenthesis for each metabolite. D ASNS expression was
knocked down using small interfering RNA (siRNA) in U2OS cells during 48 h. Cells were then treated with glutamine and BPTES as indicated for 72 h and
the ATP/ADP ratio was measured. Scramble non-targeting siRNA was used as a control. Immunoblot of ASNS levels is presented as a control of the
knockdown. E Immunoblot analysis of AMPK phosphorylation in U2OS cells treated as in (D). F Relative mRNA expression levels of ASNS as determined
by qPCR in amino acid-starved U2OS cells incubated as indicated during 72 h. G ATP/ADP ratio of amino acid-starved U2OS cells incubated with
glutamine and/or DMKG during 72 h. H Immunoblot analysis of mTORC1 downstream target (S6K, S6, and 4EBP1 phosphorylation) and AMPK
phosphorylation in U2OS cells incubated during 24 h in the presence of all amino acids with dual inhibition of GLS and/or ASNS. ASNS expression was
knocked down using small interfering RNA (siRNA) in U2OS cells during 48 h. Scramble non-targeting siRNA was used as a control. Cells were then
incubated in the presence of absence of all amino acids and/or BPTES as indicated during 24 h. I Schematic representation of the two branches model
connecting glutamine metabolism and mTORC1 signaling. Graphs show mean values ± SEM (n= 3 biologically independent experiments). *p < 0.05
(ANOVA analysis followed by a post hoc Bonferroni test). Source data are provided as a Source Data file.
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confirmed the involvement of GOT1 for the re-cycling of
aspartate from glutamate. Of note, the addition of leucine to
glutamine reduced the production of 15N-aspartate, confirming
that in the presence of leucine, glutamate is mostly catabolized
through GDH, and not through GOT1.
GABA levels were also significantly increased during glutamine
sufficiency (Supplementary 5F). Following a similar approach
than before, we observed that U2OS cells cultured with [U13C]-
glutamine showed high levels of m+4 labeled GABA (Fig. 5B),
confirming that GABA was produced directly from glutamine. As
for aspartate, a significant decrease of GABA levels was observed
in LQ treatment with respect to glutamine alone, again
confirming the potent allosteric role of leucine diverting
glutamine catabolism through GDH.
The results shown above suggest that ASNS participates in a
metabolic pathway, alternative to glutaminolysis, to metabolize
glutamine in the absence of leucine. Therefore, to link ASNS with
the production of ATP during glutamine sufficiency, we
performed a loss-of-function approach with ASNS and we
measured the levels of ATP in glutamine-treated cells. Indeed,
while neither the genetic inhibition of ASNS (gene silencing) nor
the pharmacological inhibition of GLS (using BPTES) affected
ATP levels, the inhibition of both GLS and ASNS at the same
time prevented the capacity of glutamine sufficiency to induce
ATP levels in both U2OS and HCT116 cells (Fig. 5D and
Supplementary 5H). Downstream of ATP, the co-inhibition of
both ASNS and GLS reactivated AMPK phosphorylation even
in the presence of glutamine, while it did not impact
mTORC1 signaling (Fig. 5E and Supplementary 5I). These results
confirmed that both GLS and ASNS were sufficient to metabolize
glutamine, sustaining the ATP/AMPK pathway during glutamine
sufficiency, one compensating for each other. Explaining
the involvement of ASNS in glutamine metabolism in the
absence of the allosteric input of leucine (i.e., when glutaminolysis
was inactive), we observed that the expression levels of ASNS
were high during glutamine sufficiency, but ASNS mRNA levels
decreased when leucine was co-added together with glutamine
(Fig. 5F). Similarly, ASNS mRNA levels decreased significantly in
cells incubated in the presence of DMKG, suggesting that αKG
(the end-up product of glutaminolysis) was ultimately responsible
for the inhibition of ASNS expression. The reduction of ASNS
mRNA levels by LQ was blocked by preventing αKG production
using BPTES (Fig. 5F), further confirming the role of αKG in the
control of ASNS expression. This observation correlated with
the inhibition of ATP production by glutamine when the cells are
concomitantly treated with DMKG (Fig. 5G). These results
suggested that glutaminolytic αKG prevents the metabolization of
glutamine by ASNS. Conversely, when glutaminolysis is not
operating, the absence of αKG may allow the alternative
conversion of glutamine into asparagine and glutamate by ASNS
to guarantee ATP production in the cell. The alternative
functioning of ASNS and GABA shunt, operating only when
glutaminolysis is inactive, was further confirmed by the
observation that silencing ASNS or GAD (the enzyme responsible
for the first reaction of the GABA shunt) only affected LQ-
induced mTORC1 and cell death in the presence of BPTES
(Supplementary 5J, K), confirming that both ASNS and GABA
shunt are dispensable when glutaminolysis is active.
GLS and ASNS cooperate to connect glutamine and
mTORC1 signaling. The connection between glutamine meta-
bolism and mTORC1 is a major feature of cancer cells. Gluta-
minolysis inhibition has been advocated as a potential approach
to target tumor growth through mTORC1 inhibition. However,
GLS inhibitors have failed to show a significant effect as
therapeutic drugs29,30. Indeed, in vitro GLS inhibition is not able
to inhibit mTORC1 in the presence of all amino acids, suggesting
that alternative pathways are linking glutamine metabolism and
mTORC1 activation. The results presented above identified
asparagine synthesis as a key pathway for the catabolism of glu-
tamine. Hence, we investigated if GLS and ASNS are two
necessary branches for the activation of mTORC1 in response to
nutrients. For this purpose, we investigated the impact of the dual
inhibition of ASNS and GLS on mTORC1 activation in the
presence of all amino acids for 24 h in U2OS cells, using
respectively siRNA knocking down and BPTES. As observed
before, the inhibition of GLS using BPTES was unable to inhibit
mTORC1 pathway (Fig. 5H). Likewise, ASNS downregulation did
not have a significantly impact in the phosphorylation of
mTORC1 downstream targets (S6K, S6, and 4EBP1), confirming
that GLS and ASNS can compensate for each other’s activities.
However, and confirming the model of two independent bran-
ches, the dual inhibition of ASNS and GLS significantly decreased
mTORC1 activity in the presence of all amino acids (Fig. 5H).
Consistently, while neither BPTES treatment nor ASNS silencing
could restore AMPK phosphorylation in the presence of all amino
acids, we observed an almost complete restoration of AMPK
phosphorylation upon the dual inhibition of GLS (BPTES treat-
ment) and ASNS knockdown (Fig. 5H). This result was in line
with the inhibition of mTORC1 observed in these conditions. The
need for a dual GLS and ASNS inhibition could explain the lack
of effectivity of targeting only glutaminolysis as a therapeutic
approach against cancer. This conclusion led us to propose ASNS
and GLS as dual targets that should be inhibited to allow an
efficient inhibition of mTORC1 in cancer cells.
Discussion
The results presented herein describe a dissection of the mole-
cular mechanisms connecting glutamine metabolism and
mTORC1 signaling. Previously, we had demonstrated the suffi-
ciency of glutamine metabolism, particularly glutaminolysis, to
translocate mTORC1 to the surface of the lysosome, where it is
subsequently activated27. However, until now the role of the
bioenergetic status of the cell and AMPK signaling in the
glutamine-to-mTORC1 connection was never clarified. Here,
we show that the full activation of mTORC1 downstream of
glutamine strictly requires ATP production and AMPK inhibi-
tion. In this report we also demonstrated the implication of the
ATP/AMPK axis in the induction of glutamoptosis, i.e., the
unusual apoptotic cell death induced upon the inhibition of
autophagy during nutritional imbalance12. Our results, further-
more, confirmed the glutamoptosis concept in mouse models,
validating nutritional imbalance as a potential strategic approach
to induce tumor cell death in vivo.
Contrary to our first hypothesis, the connection between glu-
tamine and ATP/AMPK axis did not require glutaminolysis, but
instead followed an alternative pathway involving the catalytic
activity of ASNS, and GABA shunt. All these three elements have
been connected previously to cancer metabolism and therapy
resistance. However, this is the first time that this alternative
pathway has been shown to mediate the connection between
glutamine and mTORC1 signaling. Although in a different con-
text, our results confirmed previous observations identifying
ASNS as a mediator of mTORC1 activation by the amino acid
asparagine7,31. Now, our results supported that ASNS metabolizes
glutamine, and in combination with GOT1 and GABA shunt,
provides with an anaplerotic entry at the TCA cycle for the
production of oxaloacetate and the subsequent ATP synthesis in
the absence of glutaminolysis. It is important to emphasize that
this alternative pathway operates only when glutaminolysis is not
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active, as glutaminolysis seems to be the most efficient mechan-
ism to feed the TCA cycle from glutamine.
Furthermore, the existence of an alternative pathway con-
necting glutamine and mTORC1 might explain the lack of effi-
cacy of targeting GLS as a potential strategy against cancer. Our
results demonstrated that, even in the absence of GLS activity,
cancer cells maintain the capacity to metabolize glutamine
through ASNS, which expression in these conditions is increased
due to the reduction in αKG production.
Although the role of leucine in mTORC1 activation has been
extensively described, most of the leucine-induced activation
mechanism for mTORC1 signaling have been described following
short-term approaches (10 min–2 h)22,25. The accepted model for
mTORC1 activation in response to amino acids32 assigns to
leucine a major role in mTORC1 activation, with additional
amino acids (such as glutamine and arginine) playing partial
activation mechanisms25,31. Now, our results indicated that leu-
cine does not show sufficiency for mTORC1 activation at long-
term, showing a permissive role for glutamine to be metabolized
through GDH for αKG production, as leucine is an allosteric
activator of GDH. In our model, and contrary to what was pro-
posed elsewhere26, the intracellular levels of leucine did not
change in response to glutamine availability. Still, our metabo-
lomics, energetic, and signaling data indicated that leucine has
almost no effect in cellular physiology in the absence of gluta-
mine, severely questioning the currently accepted model placing
leucine as the major signaling amino acid in terms of mTORC1
activation.
Our results support a model (Fig. 5I) in which glutamine is
connected to mTORC1 through two parallel, necessary pathways:
the GLS/GDH-mediated production of αKG that allows the
translocation of mTORC1 to the lysosome downstream of
Ragulator/RAG; and the ASNS-mediated production of ATP, that
allows the inhibition of AMPK and the complete activation of
mTORC1 at the surface of the lysosome. How this double
pathway interacts with the lysosomal V-ATPase-mediated
mechanism during mTORC1 activation would require further
investigations.
Methods
Cell culture. U2OS, HCT116, and HEK293A cell lines were obtained from the
American Type Culture Collection (ATCC). GFP-LC3 expressing U2OS cells were
kindly provided by Prof. Eyal Gottlieb (Cancer Research UK, Glasgow, UK). ATG+/+
MEFs and ATG5−/− MEFs were kindly provided by Prof. Patricia Boya (Centro de
Investigaciones Biologicas, Madrid, Spain). AMPK+/+ MEFs and AMPK−/− MEFs
were kindly provided by Prof. Benoit Viollet (Institute Cochin, Paris, France). All cell
lines were cultured in a high glucose DMEM base medium (D6429 Sigma-Aldrich)
supplemented with 10% v/v of inactivated foetal bovine serum, glutamine (2mM),
penicillin (100 IUml−1) and streptomycin (100 μgmL−1) at 37 °C, 5% CO2 in
humidified atmosphere. All cell lines were regularly tested for mycoplasma con-
tamination by PCR. Amino acid starvation was performed with EBSS medium (E2888
Sigma-Aldrich) complemented with glucose at a final concentration of 4.5 g L−1, at
the indicated times, ranging from 2 h to 72 h. When indicated, starvation medium was
complemented at time 0 with glutamine (2mM), leucine (0.8mM) or DMKG
(2mM). Different inhibitors or activators were used concomitantly at the following
concentrations: AICAR (0.5mM), Metformin (5mM), A769662 (100 μM), BPTES
(29 μM), and DON (40 μM).
Plasmids. The following plasmids were obtained from Addgene: RagB wt
(#19301), RagB 99 L (#19303), RagD wt (#19307), RagD 77 L (#19308) and HA
(#128034). myc-CA-AMPK plasmid was kindly provided by Prof. Benoit Viollet
(Institute Cochin, Paris, France). The plasmid transfections were carried out using
Jetpei (Polyplus Transfection) according to the manufacturer’s instructions. 70%
confluent cells were transfected with the indicated amount of plasmid, 24 h later
cells were treated as indicated.
ATP/ADP ratio measurement. Cells were seeded in a white 96 well flat bottom
plate 1 day prior the treatment. After treatment the medium was removed, the cells
washed twice with phosphate-buffered saline (PBS) and the measurement was
performed using the luminometric ATP/ADP ratio assay kit (from Sigma-Aldrich
MAK135) following the manufacturer’s instruction. The luminescence was
measured using microplate reader TriStar² LB 942 (Berthold). The results are
expressed as ratio relative levels of ATP on ADP.
Immunoblotting. U2OS or HCT116 cells were seeded and treated in 6 cm plates.
After treatment, the cells were washed twice with PBS and protein were extracted
using radioimmune precipitation assay (RIPA) lysis buffer (150 mM NaCl, 50 mM
Tris, 1 mM EGTA, 1 mM EDTA, 1% (v/v) Triton X-100, 0.5% (w/v) sodium
deoxycholate, 0.1% (v/v) SDS, pH 7.4) buffer containing a cocktail of protease
inhibitor (P8340 Sigma), PMSF 1mM, and inhibitors of phosphatases (P0044 and
P5726 Sigma). Protein lysates concentrations were determined by Bradford assay
(BCA kit from Thermo Fisher), normalized and 20 μg of protein were separated by
SDS-PAGE electrophoresis. Transfer on nitrocellulose membranes was achieved
using Trans-Blot Turbo (BioRad). Membranes were blocked in 5% BSA (TBS-
Tween 20 0.01%) and incubated overnight with the indicated antibody. After
incubation with the corresponding secondary antibody 2 h at room temperature,
the membranes were finally imaged using the ChemiDoc MP image (BioRad).
Flow cytometry. Cells were seeded the day before treatment, treated for the
indicated time and stained following with annexin V and propidium iodide (PI)
(Annexin V early apoptosis detection kit, #6592 Cell Signaling Technology)
according to the manufacturer’s instructions. Finally, cells were analysed using BD
FACSCalibur BD Biosciences flow cytometer. The analysis of the data was per-
formed using the BD CellQuestTM Pro Analysis software.
Real-time PCR. The total messengers RNAs from cells were isolated using TRIzol
reagent (Invitrogen). All samples displayed RIN greater than or equal to 8 as
determined using the RNA 6000 Nano Kit and the bioanalyzer 2100 (Agilent
Technologies). After quantification and normalization, 1 μg of total mRNA was
retrotranscribed using GoScript Reverse Transcription System (Promega). Real-
time PCR was performed in triplicate for each sample with SSO Advanced Uni-
versal SYBR Green Supermix (BioRad), 1 ng of cDNA and transcript-specific
primers using Step-One Plus Real-Time PCR system (Applied Biosystems). Specific
primers were purchased from Sigma-Aldrich. Specific primer sequences (purchased
from Sigma-Aldrich) are given below and in the Supplementary Table.
ASNS forward primer (5′–3′) CAGCGGGGACCCAATAGTAG
ASNS reverse primer (5′–3′) GTGTAGGACGTGAGCAGAAAA
Confocal microscopy. Cells were cultured on coverslips for 24 h and treated for
72 h as indicated. Cells were then fixed with paraformaldehyde 4% for 30 m at
room temperature. After fixation, cells are permeabilized 10 m using Triton-X100
0.05% and unspecific sites were blocked in BSA 5%—PBS for 30 m on a rocking
platform at room temperature. Incubation with the primary antibodies was carried
out at room temperature for 1 h and cells were incubated with the secondary
antibody for another hour at room temperature. Finally, the coverslips were
mounted on slides with Prolong containing DAPI (Invitrogen) and the samples
were imaged with a LEICA confocal SP4 microscope. U2OS stably expressing LC3-
GFP construct, were mounted directly after fixation in the same mounting medium
and imaged with a widefield LEICA microscope.
siRNA. All siRNA were ON-TARGERTplus SMARTpool (Dharmacon). The
siRNA mediated knockdown was performed using 10 nM of siRNA transfected
with INTERFERin® siRNA transfection reagent (POLYplus transfection) following
the manufacturer’s instructions. Cells were incubated in contact with the trans-
fection agent for 48 h and then treated with the indicated conditions for 24, 48, 72,
or 96 h.
Clonogenic assay. 70% confluent U2OS cells were starved in EBSS (4.5 g L−1),
treated with LQ and/or AICAR for 72 h. After treatment, 1.5 × 103 cells of each
conditions were reseeded in 3 cm plates in complete medium. Fourteen days after,
cells were fixed with paraformaldehyde 4% in PBS for 30 m and stained with crystal
violet 5% solution.
Oxygen consumption and extracellular acidification rate measurement. To
measure the OCR and extracellular acidification rate (ECAR) 5 × 104 cells were seeded
the day before experiment in XFe24 Cell Culture microplate in high glucose DMEM
base medium supplemented with 10% v/v of inactivated foetal bovine serum, gluta-
mine (4mM), penicillin (100 IUml−1) and streptomycin (100 μgmL−1). The next
day cells were washed twice in phosphate buffer saline (PBS) and medium was
replaced with the HBSS buffered with hepes complemented or not with glutamine or/
and leucine for 72 h. To eliminate residues of carbonic acid from medium, cells were
incubated for at least 30 m at 37 °C with atmospheric CO2 in a non-humidified
incubator. OCR and ECAR were assayed in a Seahorse XF-24 extracellular flux
analyser by the addition via port A of 1 μM oligomycin (port A), port B of 2.5 μM
carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP), and port C of 1 μM
rotenone and 1 μM antimycin A (port C). Three measurement cycles of 2-min mix, 2-
min wait, and 4-min measure were carried out at basal condition and after each
injection. At the end of the experiment, each well was washed twice with 50 μL of PBS
and proteins were extracted with 50 μL of RIPA lysis buffer at room temperature.
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Protein concentration in each well was measured by a BCA assay according to the
manufacturer’s instructions (Thermo).
Liquid chromatography coupled to mass spectrometry (LC–MS) for metabo-
lomics analysis. For steady-state metabolomics or metabolite tracing, 7.5 × 105
U2OS cells were seeded in a six-well plate in the evening. The day after, the cells
were washed twice with PBS and the medium was changed to EBSS (complemented
with glucose to a final concentration of 4.5 g L−1). All amino acid, glutamine,
U-13C-glutamine (Cambridge Isotope Laboratories, cat. no. CLM-1822-SP-PK),
U-15N2-glutamine (Cambridge Isotope Laboratories, cat. no. NLM-1328-PK) or
leucine were added as indicated. Cells were washed three times with PBS and the
extraction buffer (50% methanol, 30% acetonitrile, 20% water, all LC–MS grade)
was added (1 mL/1 × 106 cells). Cells were incubated in dry ice for 15 min, col-
lected, vigorously shook for 15 min at 4 °C, and left 1 h at 20 °C. Samples were
centrifuged at 15,000 × g and supernatants were transferred to autosampler vials
and stored at −80 °C until further analysis. To avoid bias due to machine drift,
samples were randomized and processed blindly.
A Q Exactive mass spectrometer coupled to a Dionex U3000 UHPLC (both
Thermo Fisher Scientific) system was used to perform the LC–MS analysis. A
Sequant ZIC-pHILIC column (150 × 2.1 mm, 5 μm) and guard column
(20 × 2.1 mm, 5 μm) (Merck Millipore) were utilized for the chromatographic
separation33. The column oven temperature was maintained at 40 °C. The mobile
phase was composed of 20 mM ammonium carbonate and 0.1% ammonium
hydroxide in water (solvent A), and acetonitrile (solvent B). The flow rate was set at
0.2 ml/min with the following gradient: 80% B for 2 min, linear decrease to 20% of
B 15 min. Both solvents were then brought back to initial conditions and
maintained for 8 min. The mass spectrometer was operated in full MS and polarity
switching mode.
The acquired spectra were analysed using XCalibur Qual Browser and XCalibur
Quan Browser software (Thermo Fisher Scientific) by referencing to an internal
library of compounds. Mass isotopologue distribution of metabolites was
determined by integration of the corresponding peaks, and correction for natural
abundance was performed using the Polly™ IsoCorrect tool from the cloud-based
platform Elucidata (https://polly.elucidata.io).
Xenograft mouse model. All animals were bred in the Animal Facility A2 of the
University of Bordeaux (institutional agreement number 133063916), led by Dr.
Benoît Rousseau. The project received the agreement from the local Ethics Com-
mittee on Animal Experiments CEEA50 of Bordeaux (agreement number APA-
FIS#10090-2017052409402562 v2). 8-week-old male NOD.Cg-Prkdcscid ll2rgtm1Wjl/
SzJ immunodeficient mice were randomly assigned to six different groups (10 mice
per group). 2 million HCT116 cells were injected in 100 μL of medium into the right
dorsal flank of the mouse subcutaneously. Tumor growth was monitored with a
calliper three times a week. Intra-peritoneal treatment was initiated when the
average volume of the tumors reached 200mm3. Three times a week 200 μL of PBS,
DMKG: 3 g/kg/week, Temsirolimus 10 g/kg/week and metformin 600mg/kg/week
were injected per mouse. After 3 weeks of treatment, mice were sacrificed, and the
tumors were collected for immunohistochemistry (IHC) analysis.
IHC. Tissue sections, 3 mm thick, were prepared from formalin-fixed paraffin-
embedded tissues and submitted to standard IHC protocols with rabbit anti-
cleaved caspase-3 Asp175 (CS #9664), phospho-S6 Ribosomal Ser235/236
(CS#4856) or phospho-AMPKα (CS#2535). The peroxidase reaction product was
visualized with 3.3′-diaminobenzidine tetrahydrochloride (DAB) reaction kit
(Vector Lab, SK-4100). Omission of the primary antibody in the immunostaining
procedure was used as a negative control. Sample analysis and images obtained
with a Leica DM6000B microscope and Leica DFC500 digital camera.
Cytosolic calcium. 1 × 105 U2OS cells were seeded onto glass coverslip (25 mm) in
DMEM. The day after, cells were treated for 48 h. Coverslips were mounted in a
recording chamber positioned on the stage of an inverted epifluorescence micro-
scope (IX70, Olympus) equipped with an ×40 UApo/340− 1.15W objective.
Single-cell cytosolic calcium imaging was performed, using Fluo2 LR-AM calcium
(2 μM added in the medium 30m before imaging). Fluo2-Leak Resistant (LR)-AM
exhibits limited compartmentalization in intracellular stores and is leakage-
resistant. Fluorescence intensity changes were normalized to the initial fluorescence
value F0 and expressed as F/F0 (relative cytosolic Ca2+ levels). One field was
acquired from each coverslip and the data were pooled from three independent
coverslips on three independent days. Data were processed using OriginPro
7.5 software (Origin Lab, Northampton, MA, USA). On graphs, data were sum-
marized as the mean ± standard deviation (SD).
Statistics. The results are expressed as a mean ± standard error of the mean of at
least three independent experiments. One-way ANOVA followed by Bonferroni’s
comparison as a post hoc test were used to evaluate the statistical difference of the
results between more than two groups. Statistical significance was estimated when
p < 0.05. Immunoblots, micrographs, and clonogenic assays are representative of at
least three biologically independent experiments.
Data availability
The authors declare that all the data supporting the findings of this study are available
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are provided with this paper.
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